Hepatit B'den D'ye Hep Güncel - page 223

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N
Engl J Med 2014;370:1879-88.
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A et al. ABT-
450, ritonavir, ombitasvir, and dasabuvir achieves 97%and 100%sustained virologic
response with or without ribavirin in treatment-experienced patients with HCV
genotype 1b infection. Gastroenterology 2014;147:359-365.
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-
450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med
EASL Recommendations on Treatment of Hepatitis C. J Hepatology 2015; 63: 199-
Hepatitis C Guidance: AASLD and the Infectious Diseases Society of America
(IDSA), in collaboration with the International Antiviral Society-USA (IAS-USA)
recommendations. HCV Guidance: Recommendations for Testing, Managing,
and Treating Hepatitis C.
(Erişim tarihi :
Sulkowski MS, Gardiner F, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson
I et al. Daklatasvir plus sofosbuvir for previously treated or untreated chronic HCV
infection. New Engl J Med 2014; 370(3):211–221.
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H et al. Sofosbuvir and
ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and
previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR):
an open-label, randomised, phase 2 trial. Lancet 2014; 383:515–523.
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL et al. Virological
response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept
phase 2A cohort study. Lancet 2015;385:1107-13.
Borgia SM, Rowaiye A. Increased eligibility for treatment of chronic hepatitis C
infection with shortened duration of therapy: Implications for access to care and
elimination strategies in Canada. Can J Gastroenterol Hepatol 2015; 29:125-9.
Osinusi A,Townsend K, Kohli A, et al. Virologic response following combined
ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV
co-infection. JAMA 2015; Feb 23. DOI: 10.1001/ jama.2015.1373. [Epub ahead of
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al.
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients
with Advanced Liver Disease. Gastroenterology 2015 May 15. J.gastro.2015.05.010.
[Epub ahead of print]
Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al.
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype
1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a
randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-
Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir
and sofosbuvir in patients with genotype 1 hepatitis C virus infection and
compensated cirrhosis: An integrated safety and efficacy analysis Hepatology.
2015 Jul;62(1):79-86.
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D et al. Treatment
of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New Engl J Med
2014;370(17): 1594–1603.
Kronik HCV Enfeksiyonunda Yeni İlaçlar
1...,213,214,215,216,217,218,219,220,221,222 224,225,226,227,228,229,230,231,232,233,...328